Analgesic effect of a bradykinin antagonist – a 1,4-benzodiazepine-2-one derivative

Aim. To study the analgesic effect of a new 1,4-benzodiazepine-2-one derivative (codenamed PAV-0056) in pain models in mice, its anti-inflammatory effect in experimental exudative inflammation in rats, and its potential ulcerogenic effect.

Materials and methods. A 1,4-benzodiazepine-2-one derivative (codenamed PAV-0056) was orally administered in polyvinylpyrrolidone (PVP) solution to 192 CD-1 mice weighing 20–25 g and 140 Sprague – Dawley rats weighing 250–300 g. The analgesic effect of the PAV-0056 compound at a dose of 0.01, 0.1, and 1 mg / kg was studied in murine acute thermal pain models (hot plate test, hot water immersion tail-flick test), acute chemogenic pain models (formalin test), and visceral spasticity-related pain models (acetic acid-induced writhing test). The anti-inflammatory effect of PAV-0056 at doses of 0.01, 0.1, and 1 mg / kg was studied in an experimental rat model of inflammation induced by subplantar administration of bradykinin and histamine. The potential ulcerogenic effect was studied in intact rats, who were injected with PAV-0056 at doses of 1 and 50 mg / kg four times. The analgesic effect of the PAV-0056 compound was compared to that of diclofenac sodium at a dose of 10 mg / kg and tramadol at a dose of 20 mg / kg. Its anti-inflammatory and potential ulcerogenic effects were compared to those of diclofenac sodium at a dose of 10 mg / kg.

Results. In the hot plate test, the PAV-0056 compound at a dose of 0.1 mg / kg increased response latency in mice by 36%, and at a dose of 1 mg / kg, it increased response latency by 46% (p < 0.05). In the tail-flick test, the PAV-0056 compound at a dose of 1 mg / kg increased response latency to heat stimulation in mice by 46% (p < 0.05). After subplantar administration of formalin, PAV-0056 at doses of 0.01–1 mg / kg had a pronounced analgesic effect, as shown by a decrease in the number of pain responses by 39–55% (p < 0.05). When mice were intraperitoneally injected with an acetic acid solution, the PAV-0056 compound at doses of 0.1 and 1 mg / kg reduced the frequency of writhings by 46 and 57%, respectively; at a dose of 0.1 mg / kg, it delayed the onset of the first writhing by 21% (p < 0.05). In experiments on rats, the PAV-0056 compound prevented the development of exudative inflammation induced by subplantar administration of bradykinin and did not have an anti-inflammatory effect in histamine-induced inflammation. PAV-0056 did not cause formation of gastric ulcers and gastric mucosal bleeding.

Conclusion. A 1,4-benzodiazepine-2-one derivative, PAV-0056, has a pronounced analgesic effect in models of thermal, chemogenic, somatic, and visceral pain in a wide range of doses (0.01–1 mg / kg). Its analgesic effects are the same as those of diclofenac sodium at a dose of 10 mg / kg and tramadol at a dose of 20 mg / kg. The analgesic effect of the PAV-0056 compound is selective, depends little on suppression of inflammatory exudation, and is caused by bradykinin antagonism. This substance has low toxicity and does not damage the gastric mucosa.

1. Kumar K.H., Elavarasi P., David C.M. Definition of pain and classification of pain disorders. JCRI. 2016;3:87–90. DOI: 10.15713/ins.jcri.112.

2. Rizzi A., Ruzza C., Bianco S., Trapella C., Calo’ G. Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test. Peptides. 2017;94:71–77. DOI: 10.1016/j.peptides.2017.07.002.

3. Lanas A., Chan F.K.L. Peptic ulcer disease. Lancet. 2017;390(10094):613–624. DOI: 10.1016/S0140-6736(16) 32404-7.

4. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2013:944.

5. Gonçalves E.C.D., Vieira G., Gonçalves T.R., Simões R.R., Brusco I., Oliveira S.M. et al. Bradykinin receptors play a critical role in the chronic postischaemia pain model. Cell Mol. Neurobiol. 2021;41(1):63–78. DOI: 10.1007/s10571-020- 00832-3.

6. Литвицкий П.Ф. Воспаление. Вопросы современной педиатрии. 2006;5(4):75–81.

7. Kaplan A.P., Joseph K., Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 2002;109(2):195–209. DOI: 10.1067/mai.2002.121316.

8. Golias Ch., Charalabopoulos A., Stagikas D., Charalabopoulos K., Batistatou A. The kinin system – bradykinin: biological effects and clinical implications. Multiple role of the kinin system – bradykinin. Hyppokratia. 2007;11(3):124–128.

9. Dziadulewicz E.K., Brown M.C., Dunstan A.R., Lee W., Said N.B., Garratt P.J. The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg. Med. Chem. Lett. 1999;9(3):463–468. DOI: 10.1016/s0960-894x(99)00015-3.

10. Wood M.R., Kim J.J., Han W., Dorsey B.D., Homnick C.F., DiPardo R.M. et al. Benzodiazepines as potent and selective bradykinin B1 antagonists. J. Med. Chem. 2003;46(10):1803– 1806. DOI: 10.1021/jm034020y.

11. Pavlovsky V.I., Tsymbalyuk O.V., Martynyuk V.S., Kabanova T.A., Semenishyna E.A., Khalimova E.I. et al. Analgesic effects of 3-substituted derivatives of 1,4-benzodiazepines and their possible mechanisms. Neurophysiology. 2013;45:427– 432. DOI: 10.1007/s11062-013-9389-y.

12. Павловский В.И., Ушаков И.Ю., Кабанова Т.А., Халимова Е.И., Кравцов В.Х., Андронати С.А. Синтез и анальгетическая активность 3-ариламино-1,2-дигидро-3н-1,4-бензо-диазепин-2-онов. Химико-фармацевтический журнал. 2015;49(9):22–27. DOI: 10.30906/0023-1134-2015-49-9-22- 27.

13. Павловский В.И., Хазанов В.А., Станкевич С.А., изобретатели; Общество с ограниченной ответственностью «Инновационные Фармакологические Разработки» (ООО «Ифар»), правопреемник. Производные 1,4-бензодиазепин-2-она и их применение. Патент Российской Федерации RU 2701557 С2. 30 сентября 2019 г. РФ.

14. Virych P.A., Shelyuk O.V., Kabanova T.A., Khalimova E.I., Martynyuk V.S., Pavlovsky V.I. et al. Effect of 3-substituted 1,4-benzodiazepin-2-ones on bradykinin-induced smooth muscle contraction. Ukr. Biochem. J. 2017;89(1):31–37. DOI: 10.15407/ubj89.01.031.

15. Hasani A., Soljakova M., Jakupi M., Ustalar-Ozgen S. Preemptive analgesic effects of midazolam and diclofenac in rat model. Bosn. J. Basic Med. Sci. 2011;11(2):113–118. DOI: 10.17305/bjbms.2011.2593.

16. Bandapati S., Podila K.S., Yadala V.R. Comparative study of antinociceptive effect of venlafaxine with tramadol by tail-flick test in animal model of mice. Natl. J. Physiol. Pharm. Pharmacol. 2021;11(6):633–637. DOI: 10.5455/njppp.2021.11.11307202001022021.

17. Gregory N.S., Harris A.L., Robinson C.R., Dougherty P.M., Fuchs P.N., Sluka K.A. An overview of animal models of pain: disease models and outcome measures. J. Pain. 2013;14(11):1255–1269. DOI: 10.1016/j.jpain.2013.06.008.

18. Чайка А.В., Черетаев И.В., Хусаинов Д.Р. Методы экспериментального доклинического тестирования анальгетического действия различных факторов на лабораторных крысах и мышах. Ученые записки Крымского федерального университета им. В.И. Вернадского. 2015;1(67):161– 173.

19. Santos L.H., Feres C.A., Melo F.H., Coelho M.M., Nothenberg M.S., Oga S. et al. Anti-inflammatory, antinociceptive and ulcerogenic activity of a zinc-diclofenac complex in rats. Braz. J. Med. Biol. Res. 2004;37(8):1205–1213. DOI: 10.1590/S0100-879X2004000800011.

20. Бондаренко Д.А., Дьяченко И.А., Скобцов Д.И., Мурашев А.Н. In vivo модели для изучения анальгетической активности. Биомедицина. 2011;2:84–94.

21. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J. Gastroenterol. 2012;18(18):2147–2160. DOI: 10.3748/wjg.v18.i18.2147.